Press coverage about Intersect ENT (NASDAQ:XENT) has trended somewhat positive on Tuesday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intersect ENT earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 46.4472060706666 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- Intersect ENT Inc (XENT) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
- Intersect ENT Inc (XENT) CFO Sells $433,951.35 in Stock (americanbankingnews.com)
- Intersect ENT, Inc. (XENT) stock is now worth at $34.65 while Analyst mean rating stands at 1.70 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- William Blair Comments on Intersect ENT Inc’s FY2018 Earnings (XENT) (americanbankingnews.com)
Shares of Intersect ENT (NASDAQ XENT) opened at $34.35 on Tuesday. The company has a market capitalization of $1,010.00, a PE ratio of -55.40 and a beta of 0.67. Intersect ENT has a 1-year low of $11.75 and a 1-year high of $35.34.
A number of brokerages have recently weighed in on XENT. Canaccord Genuity reissued a “buy” rating and issued a $36.00 price objective on shares of Intersect ENT in a report on Monday, December 11th. JPMorgan Chase & Co. raised Intersect ENT from a “neutral” rating to an “overweight” rating in a report on Tuesday, January 2nd. BidaskClub raised Intersect ENT from a “sell” rating to a “hold” rating in a report on Saturday, December 30th. Guggenheim reissued a “buy” rating and issued a $41.00 price objective on shares of Intersect ENT in a report on Friday, December 15th. Finally, Zacks Investment Research raised Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a report on Thursday, October 5th. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $33.38.
In related news, CFO Jeryl L. Hilleman sold 12,833 shares of the firm’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $27.78, for a total transaction of $356,500.74. Following the sale, the chief financial officer now directly owns 27,833 shares of the company’s stock, valued at $773,200.74. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Jeryl L. Hilleman sold 12,835 shares of the firm’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $33.81, for a total value of $433,951.35. Following the sale, the chief financial officer now directly owns 25,767 shares in the company, valued at $871,182.27. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 106,886 shares of company stock worth $3,320,094. 13.70% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This report was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://sportsperspectives.com/2018/01/16/intersect-ent-xent-receives-media-sentiment-rating-of-0-14.html.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.